Recently，In the semi -annual performance trailer disclosed by the 149 pharmaceutical listed companies，5 companies' net profit growth，48 companies have declined，Six left are uncertain。From the perspective of the segment，The medical industry has continued to slow down in the past three years，Expert said，The growth rate of the industry will decline in the next few years may be difficult to change。

 

  36 companies' net profit will increase by more than 50%

 

  According to data statistics，Among the above 149 pharmaceutical companies，It is expected that the net profit will increase by more than 50%year -on -year.。Yihua Health is a ride with a 751 -fold increase。The original main business of the company is real estate，2015 after major asset reorganization，Added medical logistics and engineering business。In this beautiful transcript，The main contribution does not come from the main growth，Instead of selling equity of Guangdong Yihua Real Estate Development Co., Ltd.。

 

  China Lao Yukuyuan is expected，Realizing net profit of 21 million yuan in the first half of the year，increase to 26 times。The main reason is that the base was smaller last year，But it also expands the signs of the reversal My stake betting appof My stake betting appGuangyuyuan's results。

 

  The company revolves around the four core products、Ding Kundan、Angong Niuhuang Wan and Niuhuang Qingxin Pill，Taking two major business departments of classic Chinese medicine and boutique Chinese medicine as axis，Create an elite sales team，Constructing a three -dimensional sales network covering the country，It plays an important role in promoting the performance of semi -annual year。

 

  Although the sales costs and management costs have increased，But with the sharp increase in operating income，Sales cost and management cost rate decreased compared to the whole year of last year。It is expected that with the annual operating income, it will continue to rise，Company sales and management costs will become stable，The pressure on net profit is gradually reduced。

 

  Companies who are expected to double the year -on -year company will still have Zixin Pharmaceutical、Ruikang Hospital、Guangji Pharmaceutical、Huashen Group、Libang Instrument、Zhejiang Zhenyuan、Polite、Fu'an Pharmaceutical、Laamei Pharmaceutical、Yong'an Pharmaceutical、Essence Pharmaceutical、Xinhecheng、Bikang shares、Ruikang Hospital、billion Fan Xinfu、Peking University Medicine、Rhine Bio、Northeast Pharmaceutical。It is worth noting that it is，These companies have increased their performance in their performance mainly due to the improvement of main business operations。

   

  A total of 48 net profit declined year -on -year。Where，There are 7 people with a decline of more than 100%。Chengzhi shares pre -losses of 24 million yuan，decreased by 381%year -on -year; 4 -ring biological losses at 1 million yuan，Fall 222%year -on -year; Shuangcheng Pharmaceutical Promotion of 17 million yuan，fell 189%year -on -year; Watson Bio had a pre -loss of 150 million yuan，Fall 130%year -on -year。

 

  For the reasons for the decline in performance，These companies are mostly called，Increase investment in scientific research，Increased scientific research expenditure; introduction stake sports betting appof Stake Sports Bettinghigh -level talents，The company's expenses remain at a higher level。or the increase in non -recurring profit and loss of the previous year，No these income this year，Caused performance decline。Watson creatures are deeply affected by & ldquo; Shandong vaccine incident & rdquo;，Operation encountered heavy damage。

 

  The pharmaceutical industry is not optimistic

 

  It is not difficult to see from the above data，Among these 149 companies，The year -on -year increase is below 30%、107 companies with a decrease of year -on -year and steps in place。Most of these companies' subdivided areas are concentrated in the pharmaceutical industry。

 

  This also reflects the characteristics of slow industry growth in the pharmaceutical industry in the past three years。

 

  The 2015 China Pharmaceutical Industry Economic Operation Index Report released by the China Pharmaceutical Industry Information Center shows，Since 2011，The value -added growth rate of the pharmaceutical industry is from 17.7%、15.2%、13.3%、12.1%，drop to about 10%in 2015。

 

  With the advancement of the new medical reform，The pharmaceutical market pattern follows great changes，Industry facing unprecedented challenges。Slows economic growth、Medical insurance control costs are getting stricter、Hospital's medicine ratio is getting smaller and smaller、Drug bidding price reduction and auxiliary medication、antibiotics、Limited liquid and other restrictions increase intensity，Especially with the comprehensive development of medical insurance control fees，Breaking the traditional growth model of the pharmaceutical industry relying on medical insurance expansion，The entire pharmaceutical industry has entered a difficult transition period。

 

  Yu Mingde, chairman of the China Medical Enterprise Management Association, told reporters，In the first half of this year，The growth rate is only 8.76%。Industry revenue growth fell below 10%，Just appeared before 2000。The moment when the demand is constantly released，The growth rate falls below the two -digit number is extremely rare。

 

  The growth rate of the industry will decline in the next few years may be difficult to change。stake sports betting appstake sports betting appAccording to the data of the Southern Institute of the State Food and Drug Administration，The sales revenue of the pharmaceutical industry was 786.4 billion yuan in 2008，By 2013, it increased to 2.15 trillion yuan，Five years of cumulative increase of 174%。

 

  In fact，The growth point of the growth rate has appeared in 2012。The growth rate of sales revenue in the pharmaceutical industry reached 26%in 2011，Fall year after year，2013 was 17.9%，2014 is 12.5%。This data has been reduced compared to 2011。

 

  At the same time as the growth rate of income is declining，profit growth is even more optimistic。The profit industry profit was 84.1 billion yuan in 2008，By the first time in 2013, it exceeded 200 billion yuan，reached 218.1 billion yuan，Cumulative increase of 159%in five years，slightly lower than the growth rate of income。But the industry's profit turning point is one year earlier than the income turning point，After the profit growth of 32.7%in 2010，Flowing all the way afterwards。The profit growth rate in 2013 was only 17.6%，Only 12% in 2014。

 

  Follow the four major changes in the industry

 

  Director of many listed companies and brokerage researchers told reporters，Investment should focus on the sub -industry that is upward in the next few years，such as blood products、Medical Service、Innovation medicine、Preparation Export、Medical Business、CRO、medicinal auxiliary materials, etc.。

 

  Li Ping Zhu, chief pharmaceutical researcher of Galaxy Securities, thinks，Four major changes in the pharmaceutical industry。First of all, it is a similar cross -border transformation like Zhongzhu Holdings，belongs to the change of the industry; followed by the change of the system，Ru Guo Pharmaceutical Department、Harbin Pharmaceutical Co., Ltd.、Enterprise vitality inspired by the reform of state -owned enterprises in Northeast Pharmaceuticals;，Such as a private hospital、Internet medical and chronic disease management、Preparation Export、Just need to take medicine、Rehabilitation Medical, etc.;，If you actively explore new business stake betting appstake online sports bettingexploration, Yibai Pharmaceutical、Changshan Pharmaceutical、Sannuo Bio。

 

  In addition，Still need to pay attention to the development of innovative drugs and the establishment of the new business model。What needs attention is，The prospect of the blood industry with scarcity of resources is available。Policy barriers in the blood industry industry high，supply and demand is more tight。

 

  The industry has been subject to insufficient plasma raw materials for many years，and non -market -oriented control。With the speed of approval at the slurry station, and the price control is released，Industry quantity and price restrictions are gradually lifted。Starting in the first half of 2015，Blood product volume and price trend tends to rise steadily。